LIPO - Lipella Renews Manufacturing Partnership with Cook MyoSite to Support Late-Stage Development of Oral Lichen Planus Therapy
2025-06-04 12:31:19 ET
The clinical-stage biotech company advancing therapies for diseases with limited or no treatment options Lipella Pharmaceuticals Inc. (Nasdaq: LIPO ), announced today that it has renewed its manufacturing collaboration agreement with Cook MyoSite, Inc. who plays a crucial role in facilitating the transition of cell-based therapies from research to clinical and commercial stages. The partnership will focus on supporting Chemistry, Manufacturing and Control (CMC) documentation for Lipella's pipeline candidates, including LP-310, an investigational non-steroidal oral rinse for Oral Lichen Planus (OLP), and LP-10.
OLP is a chronic inflammatory condition affecting the mucous membranes in the mouth, for which there are currently no approved treatments. LP-310 is positioned to address this unmet medical need as it advances toward late-stage development and scalable manufacturing.
Dr. Jonathan Kaufman , Chief Executive Officer and Co-Founder of Lipella, said, "We are pleased to renew our collaboration with Cook MyoSite, a trusted partner with a strong track record in high-quality manufacturing. This CMC collaboration is increasingly valuable to Lipella as our clinical pipeline matures toward commercializable assets."
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at lipella.com and follow us on X and LinkedIn.
This article contains sponsored content. See our disclaimer
The post Lipella Renews Manufacturing Partnership with Cook MyoSite to Support Late-Stage Development of Oral Lichen Planus Therapy appeared first on PRISM MarketView .
COMTEX_466084277/2927/2025-06-04T11:31:19